Prediction of disease relapses by multibiomarker disease activity and autoantibody status in patients with rheumatoid arthritis on tapering DMARD treatment.
about
Elevated Expression of Immunoreceptor Tyrosine-Based Inhibitory Motif (TIGIT) on T Lymphocytes is Correlated with Disease Activity in Rheumatoid Arthritis.Emerging Approaches for Validating and Managing Multiple Sclerosis Relapse.What are the dangers of biological therapy discontinuation or dose reduction strategies when treating rheumatoid arthritis?Antimodified protein antibody response pattern influences the risk for disease relapse in patients with rheumatoid arthritis tapering disease modifying antirheumatic drugs.Doctors' preferences in de-escalating DMARDs in rheumatoid arthritis: a discrete choice experiment.Optimizing treatment with tumour necrosis factor inhibitors in rheumatoid arthritis-a proof of principle and exploratory trial: is dose tapering practical in good responders?A multi-biomarker score measuring disease activity in rheumatoid arthritis patients tapering adalimumab or etanercept: predictive value for clinical and radiographic outcomes.Optimizing therapy in inflammatory arthritis: prediction of relapse after tapering or stopping treatment for rheumatoid arthritis patients achieving clinical and radiological remission.An update on diagnostic and prognostic biomarkers in inflammatory bowel disease.Multi-biomarker disease activity score as a predictor of disease relapse in patients with rheumatoid arthritis stopping TNF inhibitor treatment.Drug-free remission: the goal of the future in management of patients with rheumatoid arthritis.Mental health, fatigue and function are associated with increased risk of disease flare following TNF inhibitor tapering in patients with rheumatoid arthritis: an exploratory analysis of data from the Optimizing TNF Tapering in RA (OPTTIRA) trial.
P2860
Q37712050-51F316C6-5134-4FA2-BD8B-BF95B3973843Q37729523-DED5C0BA-7A74-4A5B-8F5F-AC32F85683A5Q38955830-E3596418-AAC1-43C4-984E-E090BF813CDCQ39669606-CF6BE557-9592-4304-86DA-792992169506Q42021846-FB9511DD-E16D-4FB4-BAC2-DEA1CEE7DF29Q47102960-EEB91B0D-C22E-469F-B993-C1B208B66415Q48808090-F7370632-9C16-4D69-814C-E4128CAEF967Q51474223-DC685DD8-0E5F-4542-8FDA-9310322028C0Q53128510-1E0549EA-638C-40E4-86B7-F0AE7FCDC0EFQ54962371-01624F59-4B71-4708-84C2-6575D59AFB3BQ54967304-B34C1D2C-D1AF-43E1-81A3-16B0DC05E2F2Q55223606-75AF9369-1579-4C3F-B933-390FDE46E335
P2860
Prediction of disease relapses by multibiomarker disease activity and autoantibody status in patients with rheumatoid arthritis on tapering DMARD treatment.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Prediction of disease relapses ...... s on tapering DMARD treatment.
@en
type
label
Prediction of disease relapses ...... s on tapering DMARD treatment.
@en
prefLabel
Prediction of disease relapses ...... s on tapering DMARD treatment.
@en
P2093
P2860
P50
P1476
Prediction of disease relapses ...... is on tapering DMARD treatment
@en
P2093
Arnd Kleyer
Bernhard Manger
Camille Figueiredo
Florian Schuch
Georg Schett
Hanns-Martin Lorenz
Hubert Nuesslein
Jayme Fogagnolo Cobra
Joerg Henes
Joerg Wendler
P2860
P304
P356
10.1136/ANNRHEUMDIS-2015-207900
P407
P577
2015-10-19T00:00:00Z